SEC Form 4 · Rule 10b5-1 trading plans
BeOne Medicines Ltd. (ONC)
- 82Trades filed under a plan
- 6Plan adoption dates stated
- 11Quarterly results prints on file
- 1Trades in the days before a print
In the 2025 filing year, BeOne Medicines Ltd. filed 17 Form 4 statements whose footnotes name a Rule 10b5-1 trading plan, by 5 reporting owners, covering 82 transactions filed under those plans and 421,093 shares. None carries the SEC's own AFF10B5ONE adoption flag; each of the 17 names a plan in a footnote. 11 results prints are on file in the same window, which is what makes the interval below measurable.
Trades filed under a plan in BeOne Medicines Ltd. 82
- Wang Xiaodong — 2025-01-07 · S · 19,251 shares
- Wang Xiaodong — 2025-01-07 · S · 11,310 shares
- Wang Xiaodong — 2025-01-07 · S · 4,260 shares
- Wang Xiaodong — 2025-01-07 · S · 5,638 shares
- Wang Xiaodong — 2025-01-07 · S · 1,301 shares
- Wang Xiaodong — 2025-02-04 · S · 9,099 shares
- Wang Xiaodong — 2025-02-04 · S · 1,519 shares
- Wang Xiaodong — 2025-02-04 · S · 2,161 shares
- Wang Xiaodong — 2025-02-04 · S · 17,805 shares
- Wang Xiaodong — 2025-02-04 · S · 9,776 shares
- Wang Xiaodong — 2025-02-04 · S · 1,400 shares
- Wu Xiaobin — 2025-02-18 · S · 19,576 shares
Plan adoption dates stated in BeOne Medicines Ltd. 6
- 2023-05-09 — stated in 2 filings
- 2024-05-13 — stated in 3 filings
- 2024-06-13 — stated in 4 filings
- 2024-08-12 — stated in 4 filings
- 2025-03-12 — stated in 2 filings
- 2025-05-14 — stated in 2 filings
Quarterly results prints on file in BeOne Medicines Ltd. 11
- 2025-02-27
- 2025-04-28
- 2025-05-07
- 2025-08-06
- 2025-08-29
- 2025-11-06
- 2026-02-26
- 2026-04-14
- 2026-05-06
- 2026-08-05
- 2026-08-26
Trades in the days before a print in BeOne Medicines Ltd. 1
- 0 days before the 2025-02-27 print — 2025-02-27 · S · Lee Chan Henry · 1,205 shares
- 6 days before the 2025-02-27 print — 2025-02-21 · S · Lee Chan Henry · 504 shares
- 6 days before the 2025-02-27 print — 2025-02-21 · S · Lee Chan Henry · 598 shares
- 6 days before the 2025-02-27 print — 2025-02-21 · S · Lee Chan Henry · 100 shares
- 6 days before the 2025-02-27 print — 2025-02-21 · S · Wang Lai · 1,327 shares
- 6 days before the 2025-02-27 print — 2025-02-21 · S · Wang Lai · 575 shares
- 6 days before the 2025-02-27 print — 2025-02-21 · S · Wang Lai · 479 shares
- 6 days before the 2025-02-27 print — 2025-02-21 · S · Wang Lai · 437 shares
- 6 days before the 2025-02-27 print — 2025-02-21 · S · Wang Lai · 1,782 shares
- 6 days before the 2025-02-27 print — 2025-02-21 · S · Wang Lai · 400 shares
- 7 days before the 2025-02-27 print — 2025-02-20 · S · Wu Xiaobin · 21,267 shares
- 7 days before the 2025-08-06 print — 2025-07-30 · S · Wang Lai · 259 shares
Interval to the next reported results date
For each transaction filed under a plan, the days between the transaction date and the company’s next results print. These are the dates the filings state, printed as an interval; the page draws no conclusion from them.
- 1Within 5 days of a print
- 18Within 10 days of a print
- 0Shortest interval, in days
- 0Trades with no later print on file
- Wu Xiaobin 2025-02-18 · S · 9 days before the 2025-02-27 print · President, COO & GM China
- Wu Xiaobin 2025-02-18 · S · 9 days before the 2025-02-27 print · President, COO & GM China
- Wu Xiaobin 2025-02-18 · S · 9 days before the 2025-02-27 print · President, COO & GM China
- Wu Xiaobin 2025-02-20 · S · 7 days before the 2025-02-27 print · President, COO & GM China
- Lee Chan Henry 2025-02-21 · S · 6 days before the 2025-02-27 print · SVP, General Counsel
- Lee Chan Henry 2025-02-21 · S · 6 days before the 2025-02-27 print · SVP, General Counsel
- Lee Chan Henry 2025-02-21 · S · 6 days before the 2025-02-27 print · SVP, General Counsel
- Wang Lai 2025-02-21 · S · 6 days before the 2025-02-27 print · Global Head of R&D
- Wang Lai 2025-02-21 · S · 6 days before the 2025-02-27 print · Global Head of R&D
- Wang Lai 2025-02-21 · S · 6 days before the 2025-02-27 print · Global Head of R&D
- Wang Lai 2025-02-21 · S · 6 days before the 2025-02-27 print · Global Head of R&D
- Wang Lai 2025-02-21 · S · 6 days before the 2025-02-27 print · Global Head of R&D
- Wang Lai 2025-02-21 · S · 6 days before the 2025-02-27 print · Global Head of R&D
- Lee Chan Henry 2025-02-27 · S · 0 days before the 2025-02-27 print · SVP, General Counsel
- Wang Lai 2025-07-29 · S · 8 days before the 2025-08-06 print · Global Head of R&D
- Wang Lai 2025-07-29 · S · 8 days before the 2025-08-06 print · Global Head of R&D
- Wang Lai 2025-07-29 · S · 8 days before the 2025-08-06 print · Global Head of R&D
- Wang Lai 2025-07-30 · S · 7 days before the 2025-08-06 print · Global Head of R&D
Adoption dates, as the filings state them
- 2023-05-09 stated in 2 filings
- 2024-05-13 stated in 3 filings
- 2024-06-13 stated in 4 filings
- 2024-08-12 stated in 4 filings
- 2025-03-12 stated in 2 filings
- 2025-05-14 stated in 2 filings
As the filings state it: “10b5-1 trading plan adopted by the Reporting Person on March 12, 2025”
Reported results dates on file
- 2025-02-27
- 2025-04-28
- 2025-05-07
- 2025-08-06
- 2025-08-29
- 2025-11-06
- 2026-02-26
- 2026-04-14
- 2026-05-06
- 2026-08-05
- 2026-08-26
A proxy statement is on file for this company in the same window, which is where a company states its own trading policy.
Other companies with plan records
- BRISTOL MYERS SQUIBB CO 1
- FMC CORP 2
- ELI LILLY & Co 4
- ABEONA THERAPEUTICS INC. 2
- HEXCEL CORP /DE/ 2
- TEVA PHARMACEUTICAL INDUSTRIES LTD 12
- Lifevantage Corp 1
- IONIS PHARMACEUTICALS INC 29
- VERTEX PHARMACEUTICALS INC / MA 22
- ARROWHEAD PHARMACEUTICALS, INC. 9
Order the document
Every company with plan records →
Form 4 statements and their footnotes from the SEC’s EDGAR full-text search, and this company’s results dates, industry classification and state of incorporation from the SEC submissions API. The page prints the dates the filings state and the interval between them; it draws no conclusion from them.